Silkworm and spider silk electrospinning: a review.

Issues of fossil fuel and plastic pollution are shifting public demand toward biopolymer-based textiles. For instance, silk, which has been traditionally used during at least 5 milleniums in China, is re-emerging in research and industry with the development of high-tech spinning methods. Various arthropods, e.g. insects and arachnids, produce silky proteinic fiber of unique properties such as resistance, elasticity, stickiness and toughness, that show huge potential for biomaterial applications. Compared to synthetic analogs, silk presents advantages of low density, degradability and versatility. Electrospinning allows the creation of nonwoven mats whose pore size and structure show unprecedented characteristics at the nanometric scale, versus classical weaving methods or modern techniques such as melt blowing. Electrospinning has recently allowed to produce silk scaffolds, with applications in regenerative medicine, drug delivery, depollution and filtration. Here we review silk production by the spinning apparatus of the silkworm Bombyx mori and the spiders Aranea diadematus and Nephila Clavipes. We present the biotechnological procedures to get silk proteins, and the preparation of a spinning dope for electrospinning. We discuss silk's mechanical properties in mats obtained from pure polymer dope and multi-composites. This review highlights the similarity between two very different yarn spinning techniques: biological and electrospinning processes.

Intramuscular olanzapine in patients with borderline personality disorder: an observational study in an emergency room.

OBJECTIVE: Despite the frequency of borderline personality disorder (BPD) in patients with acute agitation in emergency departments (EDs), there are few data about the use of intramuscular (IM) psychotropics in those patients. This is the first open-label study with olanzapine in this setting. METHOD: Measures were collected prospectively for patients with acute agitation in ED. Consent was obtained subsequently and diagnosis ascertained using the Structured Clinical Interview for DSM-IV. A group of 25 patients with severe agitation and BPD received olanzapine 10 mg IM. Efficacy and safety data are available at baseline, 2 h postinjection and at discharge. RESULTS: Significant reductions of agitation associated with good tolerance were observed 2 h after the first IM olanzapine. Sixteen percent of patients required a second IM olanzapine. CONCLUSIONS: Randomized, placebo-controlled studies are needed to confirm the efficacy of IM olanzapine in patients with acute agitation and BPD.

Oral risperidone plus oral lorazepam versus standard care with intramuscular conventional neuroleptics in the initial phase of treating individuals with acute psychosis.

Although atypical antipsychotics are now considered first line treatments for schizophrenia, intramuscular (i.m.) conventional neuroleptics are often still considered necessary in emergency treatment of acute psychoses. This European, multicentre, open-label, active-controlled trial compared oral risperidone plus oral lorazepam to standard care with i.m. conventional neuroleptics with or without lorazepam in the emergency treatment of acutely psychotic patients. Patients were allowed to choose either oral risperidone (a single dose of 2 mg and 2.0-2.5 mg lorazepam; 121 patients) or standard i.m. treatment (conventional neuroleptic with or without lorazepam; 105 patients). No additional treatment was allowed for 2 h. Primary outcome was the percentage of patients with treatment success (asleep or at least much improved on Clinical Global Impression-global improvement scale) 2 h after treatment initiation. Baseline characteristics were similar in both treatment groups. Oral risperidone plus oral lorazepam was more successful at 2 h (66.9%) and significantly non-inferior compared to standard i.m. care (54.3%; P=0.0003), and the incidence of extrapyramidal symptoms (EPS) was lower (1.7%) compared to standard i.m. care (9.5%). In acutely psychotic patients requiring emergency treatment, oral risperidone/oral lorazepam was at least as effective as i.m. conventional neuroleptic treatment with or without lorazepam. Oral risperidone plus lorazepam rapidly reduces symptoms, including aggression, and causes fewer EPS.